檢索結果 - Teerha Piratvisuth

Refine Results
  1. 1
    Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B

    Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B 由 Navavee Uman, Apichat Kaewdech, Pimsiri Sripongpun, Naichaya Chamroonkul, Teerha Piratvisuth

    出版 2025
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B

    Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B 由 Teerha Piratvisuth, George Lau, You‐Chen Chao, Rui Jin, Anuchit Chutaputti, Q.-B. Zhang, Tawesak Tanwandee, Peter Button, M. Popescu

    出版 2008
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

    Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update 由 Yun–Fan Liaw, Nancy Leung, Jia‐Horng Kao, Teerha Piratvisuth, Edward Gane, Kwang‐Hyub Han, Richard Guan, George Lau, Stephen Locarnini

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study

    Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case‐Control Study 由 Teerha Piratvisuth, Tawesak Tanwandee, Satawat Thongsawat, Wattana Sukeepaisarnjaroen, Juan Ignacio Esteban, Marta Bes, Bruno Köhler, Ying He, Magdalena Lange, David Morgenstern, Henry Lik‐Yuen Chan

    出版 2021
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

    HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B 由 Michael Fried, Teerha Piratvisuth, George Lau, Patrick Marcellin, Wan-Cheng Chow, Graham Cooksley, Kang-Xian Luo, Seung Woon Paik, Yun–Fan Liaw, Peter Button, M. Popescu

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

    Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a 由 Patrick Marcellin, Ferruccio Bonino, George Lau, Patrizia Farci, Cihan Yurdaydın, Teerha Piratvisuth, Rui Jin, Selım Gürel, Zhi‐Meng Lu, Jian Wu, M. Popescu, Stephanos J. Hadziyannis

    出版 2009
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care

    A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care 由 Christopher McGowan, Ali Monis, Bruce R. Bacon, Josep Mallolas, Fernando Lopes Gonçales, Ioannis Goulis, Fred Poordad, Nezam H. Afdhal, Stefan Zeuzem, Teerha Piratvisuth, Patrick Marcellin, Michael Fried

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

    Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study 由 Phunchai Charatcharoenwitthaya, Virasak Wongpaitoon, Piyawat Komolmit, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Teerha Piratvisuth, Theeranun Sanpajit, Chinnavat Sutthivana, Chalermrat Bunchorntavakul, Abhasnee Sobhonslidsuk, Soonthorn Chonprasertsuk, Chotipong Siripipattanamongkol, Supatsri Sethasine, Tawesak Tanwandee

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels

    Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels 由 Milan J. Sonneveld, Bettina E. Hansen, Teerha Piratvisuth, Jidong Jia, Stefan Zeuzem, Edward Gane, Yun–Fan Liaw, Qing Xie, Jenny Heathcote, Henry Lik‐Yuen Chan, Harry L.A. Janssen

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a

    Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a 由 Patrick Marcellin, George Lau, Stefan Zeuzem, E. Jenny Heathcote, Paul J. Pockros, K. Rajender Reddy, Teerha Piratvisuth, Patrizia Farci, Wan‐Cheng Chow, Jidong Jia, Woon Ki Paik, Neil Wintfeld, N. Pluck

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †

    Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # † 由 Maurizia Rossana Brunetto, F. Moriconi, Ferruccio Bonino, George Lau, Patrizia Farci, Cihan Yurdaydın, Teerha Piratvisuth, Kangxian Luo, Yuming Wang, Stephanos J. Hadziyannis, Eva Wolf, Philip McCloud, Richard Batrla, Patrick Marcellin

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Predicting response to peginterferon -2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

    Predicting response to peginterferon -2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B 由 Ferruccio Bonino, Patrick Marcellin, George Lau, S. Hadziyannis, Rui Jin, Teerha Piratvisuth, Georgios Germanidis, Cihan Yurdaydın, M. Diago, Selım Gürel, Lai My, Maurizia Rossana Brunetto, Patrizia Farci, M. Popescu, Philip McCloud

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B

    52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B 由 Teerha Piratvisuth, Piyawat Komolmit, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Henry Lik‐Yuen Chan, Mário G. Pessôa, E Fassio, Ono S, Fernando Bessone, Jorge Daruich, Stefan Zeuzem, Hugo Cheinquer, Rashidkhan Pathan, Yuhong Dong, Aldo Trylesinski

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

    Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B 由 Patrick Marcellin, George Lau, Ferruccio Bonino, Patrizia Farci, Stephanos J. Hadziyannis, Rui Jin, Zhi‐Meng Lu, Teerha Piratvisuth, Georgios Germanidis, Cihan Yurdaydın, M. Diago, Selım Gürel, Ming‐Yang Lai, Peter Button, N. Pluck

    出版 2004
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy

    Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy 由 Teerha Piratvisuth, Piyawat Komolmit, Henry C. B. Chan, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Mário G. Pessôa, E Fassio, Ono S, Fernando Bessone, Jorge Daruich, Stefan Zeuzem, Michael P. Manns, Alkaz Uddin, Yuhong Dong, Aldo Trylesinski

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region

    Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region 由 Pojsakorn Danpanichkul, Kanokphong Suparan, Banthoon Sukphutanan, Chuthathip Kaeosri, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Markos Kalligeros, Natchaya Polpichai, Yanfang Pang, Karn Wijarnpreecha, Pimsiri Sripongpun, Naichaya Chamroonkul, Mindie H. Nguyen, Suthat Liangpunsakul, Teerha Piratvisuth, Apichat Kaewdech

    出版 2024
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

    Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B 由 George Lau, Teerha Piratvisuth, Kang Luo, Patrick Marcellin, Satawat Thongsawat, Graham Cooksley, Edward Gane, Michael Fried, Wan Cheng Chow, Seung Woon Paik, Wen Yu Chang, Thomas Berg, Robert Flisiak, Philip McCloud, N. Pluck

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

    Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report 由 Henry Lik‐Yuen Chan, A. Thompson, Michelle Martinot-Peignoux, Teerha Piratvisuth, Markus Cornberg, Maurizia Rossana Brunetto, Hans L. Tillmann, Jia‐Horng Kao, Jidong Jia, Heiner Wedemeyer, Stephen Locarnini, Harry L.A. Janssen, Patrick Marcellin

    出版 2011
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  19. 19
    Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies

    Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies 由 Teerha Piratvisuth, Jinlin Hou, Tawesak Tanwandee, Thomas Berg, Arndt Vogel, Jörg Trojan, Enrico N. De Toni, Masatoshi Kudo, Anja Eiblmaier, Hanns‐Georg Klein, Johannes Kolja Hegel, Kairat Madin, Konstantin Kroeniger, Ashish Sharma, Henry Lik‐Yuen Chan

    出版 2023
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

    Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C 由 Yun–Fan Liaw, Jidong Jia, Henry Lik‐Yuen Chan, Kyunghwa Han, Tawesak Tanwandee, Wan‐Long Chuang, Dianhui Tan, X. Y. Chen, Edward Gane, Teerha Piratvisuth, L. Chen, Qing Xie, Joseph J.�Y. Sung, Cynthia Wat, Coen Bernaards, Y. Cui, Patrick Marcellin

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: